TCGA-B6-A0IQ-01A-11R-A034-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 143
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- SPERMATOGENESIS+0.230
- WNT_BETA_CATENIN_SIGNALING+0.180
- DNA_REPAIR+0.130
- MITOTIC_SPINDLE+0.120
- KRAS_SIGNALING_DN+0.090
- NOTCH_SIGNALING+0.090
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.470
- UV_RESPONSE_DN-0.460
- ANDROGEN_RESPONSE-0.440
- PROTEIN_SECRETION-0.430
- COMPLEMENT-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- TGF_BETA_SIGNALING-0.380
- BILE_ACID_METABOLISM-0.360
- COAGULATION-0.360
- INTERFERON_ALPHA_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A402-01A-11R-A239-07 | — | E | 0.918 |
| 2 | SRR29022831 | — | E | 0.915 |
| 3 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.896 |
| 4 | TCGA-E9-A1N8-01A-11R-A144-07 | — | E | 0.895 |
| 5 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.885 |
| 6 | BS_3V3KE3VT | medulloblastoma | — | 0.880 |
| 7 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.880 |
| 8 | SRR10900561 | — | — | 0.879 |
| 9 | BS_M4923M40 | ATRT | — | 0.874 |
| 10 | MNG465 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.080 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |